Last edition
News about "Sanjay Suri"
Morepen Labs Makes First US ANDA Submission
Morepen strengthens its CDMO capabilities with its first US ANDA submission, expanding formulation, bioequivalence and regulatory expertise for regulated markets.
Sanjay Suri | 30/09/2026 | By News Bureau
Morepen Begins Commercial Supplies under INR 825 Crore CDMO Contract
Morepen has started commercial supplies under its INR 825 crore CDMO mandate, completing the first INR 50 crore dispatch in Q1 FY2026-27 and strengthening its contract manufacturing business.
Sanjay Suri | 01/07/2026 | By News Bureau | 162
Morepen Laboratories Bags Zero-Observation USFDA Inspection for Fourth Time
Morepen Laboratories clears its fourth consecutive USFDA inspection at the Masulkhana facility with zero observations (NIL 483), reinforcing its CDMO strength following a INR 825 crore global manufacturing mandate.
Sanjay Suri | 21/04/2026 | By News Bureau | 419
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy